This Dividend Aristocrat is Going to Trade Ex-Dividend on May 25
LONDON, UK / ACCESSWIRE / May 24, 2017 / Active Wall St. announces its dividend coverage for Johnson & Johnson (NYSE: JNJ). Shares of Johnson & Johnson will begin trading ex-dividend on May 25, 2017. In order to qualify for a dividend check, investors must own the stock on or before May 24, which is the last day the Company's management will finalize its roster of shareholders who are eligible for dividend payment. Register with us now for your free membership at:
http://www.activewallst.com/register/
Today, AWS is promoting its ex-dividend coverage on JNJ. Get our free coverage by signing up to:
http://www.activewallst.com/register/
Dividend Declared
On April 27, 2017, Johnson & Johnson announced that its Board of Directors has declared a 5.0% increase in the quarterly dividend rate from $0.80 per share to $0.84 per share. The next quarterly dividend is payable on June 13, 2017, to shareholders of record as of the close of business on May 30, 2017. The ex-dividend date is May 25, 2017. Johnson & Johnson is among the Dividend Aristocrats, the Companies which have raised their annual dividends for at least 25 consecutive years.
"In recognition of our 2016 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the quarterly dividend for the 55th consecutive year," said Alex Gorsky, Chairman and CEO of the company.
At the new rate, Johnson & Johnson's indicated dividend on an annual basis is $3.36 per share compared to the previous rate of $3.20 per share. This represents a dividend yield of 2.64% against the average dividend yield for the Healthcare sector of 0.80%
Johnson & Johnson has a dividend pay-out ratio of 47.3% meaning the Company distributes $0.473 for every $1 earned. Analysts expect Johnson & Johnson to report earnings of $21.39 in the coming year, which means the Company should continue to be able to cover its $3.36 annual dividend.
About the Company
Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. The Company together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices.
The Company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics.
Recent Development for Johnson & Johnson
On May 17, 2017, Biosense Webster, Inc., part of the Johnson & Johnson Medical Devices Companies, announced clinical trial results from a first-in-human study evaluating the acute feasibility of an investigational radiofrequency (RF) balloon catheter in treating patients with atrial fibrillation, or Afib.
The PV Isolation with a Novel Multi-electrode Radiofrequency Balloon Catheter that allows Directionally-Tailored Energy Delivery (RADIANCE) study was a multicenter, single-arm, first-in-human feasibility study conducted between December 02, 2016, and March 08, 2017, in Europe. The study showed the RF balloon catheter could deliver directionally-tailored energy using multiple electrodes for efficient acute PVI in patients with paroxysmal atrial fibrillation.
Stock Performance
At the close of trading session on Tuesday, May 23, 2017, Johnson & Johnson's stock price was marginally up by 0.20% to end the day at $127.52. A total volume of 3.97 million shares were exchanged during the session. The Company's share price has surged 13.69% in the past twelve months and 10.68% on YTD basis. The Company's shares are trading at a PE ratio of 21.44 and have a dividend yield of 2.63%. Additionally, the stock currently has a market cap of $343.44 billion.
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
AWS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active Wall Street
